Actelion Pharmaceuticals Ltd : Actelion to present at the 31st Annual J.P.
Morgan Healthcare Conference - Delivering on our strategy
Actelion Pharmaceuticals Ltd / Actelion to present at the 31st Annual J.P.
Morgan Healthcare Conference - Delivering on our strategy . Processed and
transmitted by Thomson Reuters ONE. The issuer is solely responsible for the
content of this announcement.
ALLSCHWIL/BASEL, SWITZERLAND - 07 January 2013- Actelion Ltd (SIX: ATLN)
Actelion Ltd (SIX: ATLN) announced today that Jean-Paul Clozel, M.D., Chief
Executive Officer of Actelion, will present at the J. P. Morgan Healthcare
Conference on Tuesday, 08 January 2013 at 9.30 a.m. Pacific time / 18.30 hrs
Swiss time at the Westin St. Francis Hotel in San Francisco, CA.
Dr. Clozel will describe the progress made during 2012 in delivering on the
three elements of Actelion's strategy for value creation.
1) Sustain and grow the PAH franchise
Dr. Clozel will present an overview of Actelion's current product offerings in
the pulmonary arterial hypertension (PAH) market. He will also describe the
excellent morbidity / mortality outcome data from the SERAPHIN study with
macitentan (Opsumit®). This novel and differentiated dual endothelin receptor
antagonist (ERA) was the result of a tailored drug discovery process in
In addition, Dr. Clozel will describe the opportunity for the Company's
selective IP receptor agonist, selexipag - developed together with Nippon
Shinyaku - which has now enrolled over 1,000 patients into GRIPHON, a pivotal
study also designed to demonstrate a reduction in the risk of
Dr. Clozel will present how Actelion's franchise today and in the future has
the potential to reshape the treatment paradigm in PAH.
2) Build an additional specialty franchise
Dr. Clozel will also present the positive results with the Company's
innovative compounds, ponesimod in psoriasis and cadazolid in Clostridium
difficile associated diarrhea. At the end of 2012, mid-stage clinical studies
reported results that allowed Actelion to decide to pursue both compounds in
Phase III development. This provides Actelion with the foundation for its
mid-term goal of building an additional specialty franchise.
3) Optimize profitability
As the third element to Actelion's strategy, the company is committed to
profit growth in the coming years and to value creation for shareholders. Dr.
Clozel will present the measures taken to ensure the company can deliver on
these commitments and the company's near and mid-term core earnings guidance.
Jean-Paul Clozel, MD and Chief Executive Officer of Actelion commented: "At
last year's J. P. Morgan conference I told the audience that 2012 would be an
important year for Actelion. I am very pleased to take this opportunity to
describe the excellent progress the company has made to deliver on our
strategy for value creation. In 2013, and the years to come, Actelion will
realize the value it has created from innovation in our labs."
The presentation is available in pdf-format on www.actelion.com. To access the
live and subsequently archived webcast of the presentation, visit "Events" in
the Investor Relations section of Actelion's corporate website. An archived
replay will be available for 3 months beginning 24 hours after the live
Actelion Ltd is a biopharmaceutical company with its corporate headquarters in
Allschwil/Basel, Switzerland. Actelion's first drug Tracleer®, an orally
available dual endothelin receptor antagonist, has been approved as a therapy
for pulmonary arterial hypertension. Actelion markets Tracleer® through its
own subsidiaries in key markets worldwide, including the United States (based
in South San Francisco), the European Union, Japan, Canada, Australia and
Switzerland. Actelion, founded in late 1997, is a leading player in innovative
science related to the endothelium - the single layer of cells separating
every blood vessel from the blood stream. Actelion's over 2,400 employees
focus on the discovery, development and marketing of innovative drugs for
significant unmet medical needs. Actelion shares are traded on the SIX Swiss
Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss
Market Index SMI®).
For further information please contact:
Senior Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36
The above information contains certain "forward-looking statements", relating
to the company's business, which can be identified by the use of
forward-looking terminology such as "estimates","believes", "expects", "may",
"are expected to", "will", "will continue", "should", "would be",
"seeks","pending" or "anticipates" or similar expressions, or by discussions
of strategy, plans or intentions. Such statements include descriptions of the
company's investment and research and development programs and anticipated
expenditures in connection therewith, descriptions of new products expected to
be introduced by the company and anticipated customer demand for such products
and products in the company's existing portfolio. Such statements reflect the
current views of the company with respect to future events and are subject to
certain risks, uncertainties and assumptions. Many factors could cause the
actual results, performance or achievements of the company to be materially
different from any future results, performances or achievements that may be
expressed or implied by such forward-looking statements. Should one or more of
these risks or uncertainties materialize, or should underlying assumptions
prove incorrect, actual results may vary materially from those described
herein as anticipated, believed, estimated or expected.
Press Release PDF
This announcement is distributed by Thomson Reuters on behalf of Thomson
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.
Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE
--- End of Message ---
Actelion Pharmaceuticals Ltd
Gewerbestrasse 16 Allschwil Switzerland
Press spacebar to pause and continue. Press esc to stop.